Analysis of the efficiency of using different triple-therapy schemes of helicobacter pylori eradication in children with destructive changes of the duodenal mucosa
DOI:
https://doi.org/10.24959/cphj.14.1302Keywords:
Helicobacter pylori, eradication schemes, children, chronic gastroduodenal pathology, erosion of the mucous membrane, duodenal ulcer diseaseAbstract
The study was conducted in the gastroenterological department of Donetsk City Children Clinical Hospital No. 1. The study involved 120 children aged 12-17 years old with erosive and ulcerative changes in the duodenal mucosa on the background of Helicobacter pylori persistence. All patients were divided into four groups of comparison. Patients of group I received omeprazole + amoxicillin + nifuratel, group II – amoxicillin + clarithromycin + colloidal bismuth subcitrate, group III – omeprazole + clarithromycin + nifuratel, group IV – omeprazole + clarithromycin + amoxicillin. The efficiency of different methods of Helicobacter pylori eradication in children with duodenal ulcer and erosive bulbitis has been studied. None of the schemes of anti-HP therapy used allows to achieve Helicobacter pylori elimination in 100% of the cases in children with destructive changes of duodenal mucosa. It has been found that the combination of clarithromycin and amoxicillin with omeprazole or colloidal bismuth subcitrate allows to achieve eradication of Helicobacter pylori in 80% of cases in children with erosive and ulcerative changes in the duodenal mucosa. It is necessary to develop new, combined, more effective schemes for the treatment of erosive-ulcerative changes in the duodenal mucosa, which would be available and safe for application in pediatric practice.
References
Видманова Т.А., Жукова Е.А., Вискова И.Н. // Мед. альманах. – 2011. – №6 (19). – С. 182-184.
Осадчук М.М., Купаев В.И., Осадчук А.М. // Практ. медицина. – 2012. – №1 (56). – С. 16-21.
Файзуллина Р.А., Абдуллина Е.В. // Практ. медицина. – 2011. – №1 (49). – С. 74-78.
Щербаков П.Л. // Эксперим. и клин. гастроэнтерол. – 2008. – №8. – С. 46-51.
Hu T.H., Chuah S.K., Hsu P.I. et al. // Am. J. Med. Sсi. – 2011. – Vol. 342 (3). – P. 177-181.
Liou J.M., Chen C.C., Chen M.J. et al. // J. Antimicrob. Chemother. – 2011. – Vol. 66 (8). – P. l847-1852.
Malfertheiner P., Megraud F., O’Morain C.A. et al. European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report // Gut. – 2012. – Vol. 61 (5). – P. 646-664.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
